Skip to content

Exhaled Markers in Asthma during Inhaled steroid Lowering

Exhaled Markers in Asthma during Inhaled steroid Lowering - EMAIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35841
Enrollment
30
Registered
2011-07-29
Start date
2012-04-05
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma exacerbatie

Interventions

Breath measurements by electronic nose platform and GC-MS and sputum and blood biomarkers will be monitored at baseline, and during withdrawal and restoration of inhaled steroids.

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age: at least 18 years. - Mild to moderately severe persistent asthma according to the GINA criteria. - Using at least a daily dose of inhaled corticosteroids (* 500 ug ICS fluticasone or equivalent). - Controlled or partly controlled asthma according to the criteria by GINA. - Exacerbations: one or more in the past 2 years. - Non-smoking or stopped smoking more than 12 months ago and a total maximum of 5 pack years. - No other clinically significant abnormality on history and clinical examination. - Able to give written and dated informed consent prior to any study-specific procedures.

Exclusion criteria

Exclusion criteria: - Change in the dose of inhaled corticosteroids within 4 weeks prior to screening. - A course of oral corticosteroids, antibiotics or a respiratory infection within 4 weeks prior to the study. - Use of ipratropium, anti-IgE or oral corticosteroids. - Pregnancy. - Concomitant disease or condition which could interfere with the conduct of the study, or which treatment might interfere with the conduct of the study, or which would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study. - Unwillingness or inability to comply with the study protocol for any other reason.

Design outcomes

Primary

MeasureTime frame
Change in eNose breathprint at loss of control compared to stable condition, after completion of 8 weeks steroid withdrawal phase.

Secondary

MeasureTime frame
1. Individual biomarkers in sputum, blood ann exhaled breath condensate (EBC) that are associated with asthma control and with electronic nose ann GC-MS breathprints. 2. Hemostatic activity.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)